<DOC>
	<DOC>NCT00351169</DOC>
	<brief_summary>To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>Male or female aged 18 to 65 years A documented diagnosis of major depressive disorder Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
</DOC>